Montenegro’s pharmaceutical sector, small in size but strategically important, rarely makes front-page business news. Yet the recent developments surrounding Galenika Crna Gora — a subsidiary of the once-dominant Serbian pharmaceutical producer Galenika — have brought an old debate back to the forefront: what does Montenegro do with industrial assets caught between legacy ownership structures, failed privatisations, and unclear strategic direction?
This November, the company announced another attempt to sell a portion of its assets valued at approximately €3.4 million, a step interpreted by observers as part of a protracted process of restructuring. These assets, which include production spaces, land, and auxiliary facilities, have been on the table for years, with previous tenders attracting either weak interest or bids far below expectations.
The issue is emblematic of the country’s wider economic challenge: smaller companies that once served Yugoslav or regional supply chains have struggled to reinvent themselves in a market dominated by modern logistics, consolidated pharmaceuticals, and globalised medical-supply routes. For Galenika Crna Gora, the situation is compounded by legal processes related to insolvency, debts, and questions over the long-term viability of certain operations.
Industry analysts say the government’s approach has been unclear. On one hand, Montenegro is pushing forward with a strategy to modernise its healthcare infrastructure and expand its imports of higher-quality medicines. On the other, it has not yet articulated a clear industrial policy for older manufacturing assets like Galenika’s. Without such clarity — and without a targeted plan for blending foreign investment with local industrial retention — the market is left in a vacuum.
The failed tender rounds point to a deeper hesitation among investors. Pharmaceutical production requires scale, capital, and the ability to plug into larger regional supply networks. Montenegro’s domestic market is too small to support manufacturing without export orientation. Buyers therefore view these assets not as a ready-to-operate business, but as real-estate opportunities or potential logistics sites, which lowers perceived value and complicates negotiations.
The question now is whether this latest sale attempt will succeed. Given Montenegro’s ongoing push toward EU alignment, foreign investors may show interest if the assets can be repurposed or integrated into broader regional supply strategies — particularly for medical packaging, distribution centres, or specialised production lines. But unless a strong industrial buyer emerges, it is likely that the process will continue to move slowly.
For policymakers and investors, the message is clear: Montenegro’s manufacturing inheritance remains unresolved. The Galenika Crna Gora case is not an isolated issue but a mirror reflecting the structural dilemmas of smaller Adriatic economies transitioning out of post-industrial uncertainty. The next steps in the sale process will show whether the country is capable of turning legacy industrial sites into modern economic opportunities — or whether these assets will continue to drift between tenders, trapped in administrative limbo.
